Zegerid

PreclinicalSmall molecule

Bayer

Zegerid is one of 7 small molecule programs targeting Barrett's esophagus. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Barrett's EsophagusTerminated

Barrett's EsophagusPreclinical

Terminated

Competition

Competitive Landscape

7 competitors in Barrett's Esophagus

#DrugCompanyPhaseTrials

Dexilant

Takeda

Approved

1 2

Nolvadex

AstraZeneca

Approved

—3

Photofrin

PPinnacle Biologics Inc.

Approved

—4

Protonix

WWyeth-Lederle Vaccines

Zantac 150

Avastin

Zegerid

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Gastric Acid1 trial

Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid Suppression

Completed·PProcter and Gamble·Phase 4·NCT00808769·30 enrolled

Barrett's esophagus1 trial

Assessment of Zegerid on Esophageal pH in Patients With Barrett's Esophagus

Terminated·SStanford University·N/A·NCT01129778·27 enrolled

Fasting Conditions1 trial

A Three-Period Study to Investigate the Relative Bioavailability and Pharmacodynamic Profiles of a Zegerid 20mg Capsule, Zegerid 20mg Powder for Oral Suspension and Losec 20mg Capsule in Healthy Adult Volunteers Under Fasting Conditions

Completed·NNorgine·Phase 1·NCT01710995·20 enrolled

Gastric1 trial

Study to Compare Gastric Inhibition of Two Proton Pump Inhibitors (CL2008-18)(P07815)(COMPLETED)

Completed· Bayer logo

Bayer·Phase 3·NCT01005719·63 enrolled

TED1 trial

Pharmacodynamic Study Comparing the Effects of Two Different Forms of Omeprazole (P07812) (COMPLETED)

Completed· Bayer logo

Bayer·Phase 3·NCT01077076·30 enrolled

1 more indication

Gastroesophageal Reflux Disease1 trial

Phase III Study Comparing Zegerid® With Losec® for the Relief of Heartburn Associated With Gastroesophageal Reflux Disease

Completed·NNorgine·Phase 3·NCT01493089·239 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Zegerid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zegerid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zegerid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Bayer

Zegerid

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Gastric Acid1 trial

Barrett's esophagus1 trial

Fasting Conditions1 trial

Gastric1 trial

TED1 trial

Gastroesophageal Reflux Disease1 trial

References

Drug Info

Quick Facts

Related News